SAFETY AND EFFICACY OF SEMAGLUTIDE, LIRAGLUTIDE AND SIBUTRAMINE IN THE TREATMENT OF OBESITY

Abstract

This article is an integrative literature review built through articles and publications from 2006 to 2022. This review used 21 of these articles for textual elaboration and had as inclusion criteria the materials published in health journals, PUBMed and SciELO. It is noteworthy the growth of obesity in the world population and the consequent increase in drug therapy. The study evaluates the efficacy and safety of the substances Liraglutide, Semaglutide and Sibutramine, used in therapy, based on their mechanisms of action in the treatment of obesity, considering the documented adverse reactions and the importance of the pharmaceutical professional in aiding the therapy, and as an important part of ensuring and monitoring the safety and efficacy of treatment. The arrival of GLP-1 agonists as a treatment for obesity brings a less harmful alternative when compared to older pharmacological methods, such as treatment with sibutramine. More studies are needed to build more evidence.